BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28830827)

  • 1. Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.
    Taylor NJ; Mitra N; Goldstein AM; Tucker MA; Avril MF; Azizi E; Bergman W; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes AM; Ghiorzo P; Grazziotin TC; Hansson J; Harland M; Hayward NK; Hocevar M; Höiom V; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer JM; Perić B; Pjanova D; Pritchard A; Puig S; van der Stoep N; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA;
    J Invest Dermatol; 2017 Dec; 137(12):2606-2612. PubMed ID: 28830827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations.
    Bishop JA; Wachsmuth RC; Harland M; Bataille V; Pinney E; MacK P; Baglietto L; Cuzick J; Bishop DT
    J Invest Dermatol; 2000 Jan; 114(1):28-33. PubMed ID: 10620111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
    Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N;
    J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
    Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
    Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal assessment of the nevus phenotype in a melanoma kindred.
    Florell SR; Meyer LJ; Boucher KM; Porter-Gill PA; Hart M; Erickson J; Cannon-Albright LA; Pershing LK; Harris RM; Samlowski WE; Zone JJ; Leachman SA
    J Invest Dermatol; 2004 Sep; 123(3):576-82. PubMed ID: 15304099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
    Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
    J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
    Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
    Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
    Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
    J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.
    Chaudru V; Chompret A; Bressac-de Paillerets B; Spatz A; Avril MF; Demenais F
    J Natl Cancer Inst; 2004 May; 96(10):785-95. PubMed ID: 15150307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.
    Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
    Genet Med; 2018 Sep; 20(9):1087-1090. PubMed ID: 29215650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
    Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
    J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetics of hereditary melanoma and nevi. 1998 update.
    Greene MH
    Cancer; 1999 Dec; 86(11 Suppl):2464-77. PubMed ID: 10630172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele.
    Bertram CG; Gaut RM; Barrett JH; Pinney E; Whitaker L; Turner F; Bataille V; Dos Santos Silva I; J Swerdlow A; Bishop DT; Newton Bishop JA
    J Invest Dermatol; 2002 Oct; 119(4):961-5. PubMed ID: 12406345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
    Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
    Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A search for CDKN2A/p16INK4a mutations in melanocytic nevi from patients with melanoma and spouse controls by use of laser-captured microdissection.
    Wang H; Presland RB; Piepkorn M
    Arch Dermatol; 2005 Feb; 141(2):177-80. PubMed ID: 15724013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
    Helgadottir H; Höiom V; Tuominen R; Nielsen K; Jönsson G; Olsson H; Hansson J
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27287845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
    Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
    JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree.
    Florell SR; Meyer LJ; Boucher KM; Grossman D; Cannon-Albright LA; Harris RM; Samlowski WE; Zone JJ; Leachman SA
    J Invest Dermatol; 2008 Aug; 128(8):2122-5. PubMed ID: 18337833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.